What Genesis Therapeutics does
Genesis Molecular AI (formerly Genesis Therapeutics) develops molecular AI for small-molecule drug discovery, combining generative and predictive foundation models with “physics + AI” workflows to support iterative structure/design cycles. The company’s AI platform is centered on GEMS (Genesis Exploration of Molecular Space), which Genesis describes as an AI operating system for molecular design and validation workflows that power both internal discovery programs and major pharma collaborations. Genesis also publishes/model-releases research artifacts in connection with its foundation-model efforts, including Pearl (a drug–protein structure prediction foundation model) and DeCAF-Pearl (a distilled/accelerated cofolding variant described as enabling higher-throughput generation and synthetic-data production). For commercialization, Genesis positions a partner-centric discovery model: large pharmaceutical partners select collaboration targets, Genesis deploys GEMS to generate and optimize candidates, and the partner supplies proprietary experimental data back into model training (with economics structured around upfront payments plus milestone payments and royalties, depending on the agreement). As of 2026-08-23, Genesis’ most recent major disclosed business update is the May 20, 2026 expansion of its Incyte collaboration, under which Genesis is set to receive $120M upfront consideration and potentially up to $232M per program in development/regulatory/sales milestones, with additional upside if milestones are achieved across initial targets.